Log in

Relevant bibliographies by topics / Drug development Drug design / Journal articles

To see the other types of publications on this topic, follow the link: Drug development Drug design.

Journal articles on the topic 'Drug development Drug design'

Author: Grafiati

Published: 4 June 2021

Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug development Drug design.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ranade, Vasant V. "Drug Metabolism in Drug Design and Development." American Journal of Therapeutics 16, no. 5 (2009): 467. http://dx.doi.org/10.1097/mjt.0b013e3181728805.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gupta, Satya Prakash. "Roles of Fluorine in Drug Design and Drug Action." Letters in Drug Design & Discovery 16, no. 10 (2019): 1089–109. http://dx.doi.org/10.2174/1570180816666190130154726.

Full text

Abstract:

The article discusses the basic properties of fluorine atom that have made it so useful in drug development. It presents several examples of therapeutically useful drugs acting against many life-threatening diseases along with the mechanism as to how fluorine influences the drug activity. It has been pointed out that fluorine, due to its ability to increase the lipophilicity of the molecule, greatly affects the hydrophobic interaction between the drug molecule and the receptor. Because of its small size, it hardly produces any steric effect, rather due to electronic properties enters into elec

APA, Harvard, Vancouver, ISO, and other styles

3

Hovgaard, Lars. "Biopharmaceutical Drug Design and Development." Journal of Controlled Release 66, no. 2-3 (2000): 323. http://dx.doi.org/10.1016/s0168-3659(99)00284-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

JOSHI, H. "Drug development and imperfect design☆." International Journal of Pharmaceutics 343, no. 1-2 (2007): 1–3. http://dx.doi.org/10.1016/j.ijpharm.2007.06.046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Papavassiliou, Athanasios G. "Transcription Factor-Based Drug Design in Anticancer Drug Development." Molecular Medicine 3, no. 12 (1997): 799–810. http://dx.doi.org/10.1007/bf03401717.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

De, Baishakhi, Koushik Bhandari, Francisco J. B. Mendonça, Marcus T. Scotti, and Luciana Scotti. "Computational Studies in Drug Design Against Cancer." Anti-Cancer Agents in Medicinal Chemistry 19, no. 5 (2019): 587–91. http://dx.doi.org/10.2174/1871520618666180911125700.

Full text

Abstract:

Background: The application of in silico tools in the development of anti cancer drugs. Objective: The summing of different computer aided drug design approaches that have been applied in the development of anti cancer drugs. Methods: Structure based, ligand based, hybrid protein-ligand pharmacophore methods, Homology modeling, molecular docking aids in different steps of drug discovery pipeline with considerable saving in time and expenditure. In silico tools also find applications in the domain of cancer drug development. Results: Structure-based pharmacophore modeling aided in the identific

APA, Harvard, Vancouver, ISO, and other styles

7

Olgen, Sureyya. "Overview on Anticancer Drug Design and Development." Current Medicinal Chemistry 25, no. 15 (2018): 1704–19. http://dx.doi.org/10.2174/0929867325666171129215610.

Full text

Abstract:

Background: Many impediments of current anti-cancer therapies have urged scientists to discover new agents. As a result of growing spectrums of new targets and strategies and recent biological and biotechnological progresses, many anti-cancer agents such as monoclonal antibodies, small molecule tyrosine kinase inhibitors and epigenetic drugs have been reached to clinical trials. Objectives: This review helps to understand the rationale for the development of inhibitors against major targets such as cell growth, proliferation, survival, angiogenesis and recent targets such as proteasome, heat s

APA, Harvard, Vancouver, ISO, and other styles

8

Barrawaz, Aateka Y. "COMPUTER AIDED DRUG DESIGN: A MINI-REVIEW." Journal of Medical Pharmaceutical And Allied Sciences 9, no. 5 (2020): 2584–91. http://dx.doi.org/10.22270/jmpas.v9i5.971.

Full text

Abstract:

New drug discovery and development process is considered much complex process which is time consuming and resources accommodating too. So computer aided drug design are being broadly used to enhance the effectiveness of the drug discovery and development process which ultimately saves time and resources. Various approaches to Computer aided drug design are evaluated to shows potential techniques in accordance with their needs. Two approaches are considered to designing of drug first one is structure-based and second one is Ligand based drug designs. In this review, we are discussing about high

APA, Harvard, Vancouver, ISO, and other styles

9

Vilos, Cristian. "Nanotechnology in Preclinical and Clinical Drug Development." International Journal of Medical and Surgical Sciences 1, no. 1 (2018): 73–93. http://dx.doi.org/10.32457/ijmss.2014.011.

Full text

Abstract:

Nanotechnology is generating a strong impact in preclinical and clinical drug development. The diversity of current nanotechnologies offers a broad platform used to enhance the performance of drug discovery screening, to develop sensitive and specific methods used to unveil the mechanisms behind the actions of drugs, to determine the function and interaction between molecules, and to study the physiological and pathological changes of cellular components. In addition, advancements in nanobiotechnology have led to the design of new nanomaterial-based drug candidates that present a novel approac

APA, Harvard, Vancouver, ISO, and other styles

10

Chelamalla, Radhika. "Drug resistance: important criteria for cancer drug development." Pharmaceutical and Biological Evaluations 4, no. 2 (2017): 127. http://dx.doi.org/10.26510/2394-0859.pbe.2017.19.

Full text

Abstract:

Molecularly targeted agents light at end of tunnel to resolve therapeutics by drawing together morbidity and mortality in patients by the whole of cancer. However, still an urgent has a passion for preferably effective anticancer compounds, state-of-the-art preclinical abused substance evaluations largely overlook to answer a need the demand. New preclinical strategies, including the review of with all the extras mouse models and co-clinical design designs, are for used to boost the predictive price tag of animal-based translational aries research. Here, we saw in a new light the society of bo

APA, Harvard, Vancouver, ISO, and other styles

11

Kumar, B., and G. Jeyabalan. "Design and Development of Dual Drug Loaded Niosomes Containing Amoxicillin and Clavulanic acid." Asian Pacific Journal of Health Sciences 4, no. 2 (2017): 206–13. http://dx.doi.org/10.21276/apjhs.2017.4.2.33.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Borisov, D. V., and A. V. Veselovsky. "Ligand-receptor binding kinetics in drug design." Biomeditsinskaya Khimiya 66, no. 1 (2020): 42–53. http://dx.doi.org/10.18097/pbmc20206601042.

Full text

Abstract:

Traditionally, the thermodynamic values of affinity are considered as the main criterion for the development of new drugs. Usually, these values for drugs are measured in vitro at steady concentrations of the receptor and ligand, which are differed from in vivo environment. Recent studies have shown that the kinetics of the process of drug binding to its receptor make significant contribution in the drug effectiveness. This has increased attention in characterizing and predicting the rate constants of association and dissociation of the receptor ligand at the stage of preclinical studies of dr

APA, Harvard, Vancouver, ISO, and other styles

13

Zeng, Huahui, and Xiangxiang Wu. "Alzheimer's disease drug development based on Computer-Aided Drug Design." European Journal of Medicinal Chemistry 121 (October 2016): 851–63. http://dx.doi.org/10.1016/j.ejmech.2015.08.039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Kuwata, Kazuo. "S2g1-3 Dynamics Based Drug Design for Prion Diseases(S2-g1: "Drug Development",Symposia,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S126. http://dx.doi.org/10.2142/biophys.46.s126_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Fuji, Hideyoshi, Junko Tatsumi, Jun Komano, and Tyuji Hoshino. "2P586 Development of HIV-1 RNaseH inhibitor by Computer-Assisted Drug Design(55. Drug design and delivery,Poster Session,Abstract,Meeting Program of EABS &BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S442. http://dx.doi.org/10.2142/biophys.46.s442_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Huang, Sheng-He, Hongwei Xia, Feng Chi, Naila K. Khalaf, and Ambrose Jong. "Chemoinfectomics in Drug Design and Development." Anti-Infective Agents 11, no. 2 (2013): 100–108. http://dx.doi.org/10.2174/2211352511311020003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Jog, Rajan, and Diane J. Burgess. "Nanoamorphous drug products – Design and development." International Journal of Pharmaceutics 553, no. 1-2 (2018): 238–60. http://dx.doi.org/10.1016/j.ijpharm.2018.10.046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Lou, Lillian L., and John C. Martin. "Selected Thoughts on Hydrophobicity in Drug Design." Molecules 26, no. 4 (2021): 875. http://dx.doi.org/10.3390/molecules26040875.

Full text

Abstract:

The fundamental aim of drug design in research and development is to invent molecules with selective affinity towards desired disease-associated targets. At the atomic loci of binding surfaces, systematic structural variations can define affinities between drug candidates and biomolecules, and thereby guide the optimization of safety, efficacy and pharmacologic properties. Hydrophobic interaction between biomolecules and drugs is integral to binding affinity and specificity. Examples of antiviral drug discovery are discussed.

APA, Harvard, Vancouver, ISO, and other styles

19

Tang, Siu Wa, and Wayne H. Tang. "Opportunities in Novel Psychotropic Drug Design from Natural Compounds." International Journal of Neuropsychopharmacology 22, no. 9 (2019): 601–7. http://dx.doi.org/10.1093/ijnp/pyz042.

Full text

Abstract:

Abstract Multiple initiatives at the national and international level support natural drug discovery. Psychiatrists and patients are not well informed about natural psychotropics in general. Existing antidepressant and antipsychotic drugs were developed from atropine, a natural product. Subsequent drug developments were largely based on extension and modification of earlier molecular scaffolds. This limits their mechanisms of action to similar neuropathways. Natural psychotropic substances, particularly those with hallucinogenic and psychedelic properties and different chemical structures, may

APA, Harvard, Vancouver, ISO, and other styles

20

Kim, Jong H., Kathleen L. Chan, Luisa W. Cheng, et al. "High Efficiency Drug Repurposing Design for New Antifungal Agents." Methods and Protocols 2, no. 2 (2019): 31. http://dx.doi.org/10.3390/mps2020031.

Full text

Abstract:

Current antifungal interventions have often limited efficiency in treating fungal pathogens, particularly those resistant to commercial drugs or fungicides. Antifungal drug repurposing is an alternative intervention strategy, whereby new utility of various marketed, non-antifungal drugs could be repositioned as novel antifungal agents. In this study, we investigated “chemosensitization” as a method to improve the efficiency of antifungal drug repurposing, wherein combined application of a second compound (viz., chemosensitizer) with a conventional, non-antifungal drug could greatly enhance the

APA, Harvard, Vancouver, ISO, and other styles

21

Sehgal, Vijay Kumar, Supratik Das, and Anand Vardhan. "Computer Aided Drug Designing." International Journal of Medical and Dental Sciences 6, no. 1 (2017): 1433. http://dx.doi.org/10.18311/ijmds/2017/18804.

Full text

Abstract:

Designing of drugs and their development are a time and resource consuming process. There is an increasing effort to introduce the role of computational approach to chemical and biological space in order to organise the design and development of drugs and their optimisation. The role of Computer Aided Drug Designing (CADD) are nowadays expressed in Nanotechnology, Molecular biology, Biochemistry etc. It is a diverse discipline where various forms of applied and basic researches are interlinked with each other. Computer aided or in Silico drug designing is required to detect hits and leads. Opt

APA, Harvard, Vancouver, ISO, and other styles

22

Kawasaki, Nana. "Monoclonal Antibody Drugs: Quality by Design Approach for the Drug Development." Journal of the Mass Spectrometry Society of Japan 66, no. 4 (2018): 150–53. http://dx.doi.org/10.5702/massspec.s18-30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Lopalco, Antonio, and Nunzio Denora. "Paediatric Formulation: Design and Development." International Journal of Molecular Sciences 21, no. 19 (2020): 7118. http://dx.doi.org/10.3390/ijms21197118.

Full text

Abstract:

The development of medicines designed for children can be challenging since this distinct patient population requires specific needs. A formulation designed for paediatric patients must consider the following aspects: patient population variability; dose flexibility; route of administration; patient compliance; drug and excipient tolerability. The purpose of this Special Issue entitled “Paediatric Formulation: Design and Development” is to provide an update on both state-of-the-art methodology and operational challenges in the design and development of paediatric formulations. It aims at re-ev

APA, Harvard, Vancouver, ISO, and other styles

24

Li, Ping, Bing Qi, Kun Li, et al. "Development of Magnetic-Fluorescent Bifunctional Drug Delivery System with Dual Drug Content and Enhanced Fluorescence." Journal of Nanoscience and Nanotechnology 18, no. 12 (2018): 8094–98. http://dx.doi.org/10.1166/jnn.2018.16393.

Full text

Abstract:

The drug delivery system incorporating magnetic particles and fluorescent marker would be uniquely effective for magnetic targeting and fluorescent tracing. In order for the fluorescent signals to reflect the drug delivery accurately, the separation of the fluorescent label and drugs must be counteracted. The objective of the current study was to design a method of binding drugs to the fluorescent material so that the drug diffusion and delivery could be monitored precisely. To obtain fluorescently-labeled drugs, complexes of the rare earth ion with a single drug benzimidazole (Tb(Bim)3), and

APA, Harvard, Vancouver, ISO, and other styles

25

Flaherty, Keith T., Dung T. Le, and Steven Lemery. "Tissue-Agnostic Drug Development." American Society of Clinical Oncology Educational Book, no. 37 (May 2017): 222–30. http://dx.doi.org/10.1200/edbk_173855.

Full text

Abstract:

The U.S. Food and Drug Administration (FDA) has approved drugs to treat patients with tumor types based on a single anatomic site, such as renal cell carcinoma or melanoma, rather than on a biomarker alone. This standard approach is based on a number of factors, including heterogeneity of drug effects in different biomarker-positive tumor types. Additionally, drug development for some drugs was primarily directed toward a specific genomic abnormality in a specific tumor type (e.g., drugs for anaplastic lymphoma kinase [ALK] fusion-positive non–small cell lung cancer). In such cases, difference

APA, Harvard, Vancouver, ISO, and other styles

26

Aliev, Gjumrakch. "Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)." Current Pharmaceutical Design 22, no. 7 (2016): 765–67. http://dx.doi.org/10.2174/138161282207160127173155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Pedreira, Júlia G. B., Lucas S. Franco, and Eliezer J. Barreiro. "Chemical Intuition in Drug Design and Discovery." Current Topics in Medicinal Chemistry 19, no. 19 (2019): 1679–93. http://dx.doi.org/10.2174/1568026619666190620144142.

Full text

Abstract:

The medicinal chemist plays the most important role in drug design, discovery and development. The primary goal is to discover leads and optimize them to develop clinically useful drug candidates. This process requires the medicinal chemist to deal with large sets of data containing chemical descriptors, pharmacological data, pharmacokinetics parameters, and in silico predictions. The modern medicinal chemist has a large number of tools and technologies to aid him in creating strategies and supporting decision-making. Alongside with these tools, human cognition, experience and creativity are f

APA, Harvard, Vancouver, ISO, and other styles

28

Rekka, Eleni A., Panos N. Kourounakis, and Maria Pantelidou. "Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design." Current Topics in Medicinal Chemistry 19, no. 4 (2019): 276–91. http://dx.doi.org/10.2174/1568026619666190129122727.

Full text

Abstract:

Background: The biotransformation of xenobiotics is a homeostatic defensive response of the body against bioactive invaders. Xenobiotic metabolizing enzymes, important for the metabolism, elimination and detoxification of exogenous agents, are found in most tissues and organs and are distinguished into phase I and phase II enzymes, as well as phase III transporters. The cytochrome P450 superfamily of enzymes plays a major role in the biotransformation of most xenobiotics as well as in the metabolism of important endogenous substrates such as steroids and fatty acids. The activity and the poten

APA, Harvard, Vancouver, ISO, and other styles

29

Lin, Eugene, Chieh-Hsin Lin, and Hsien-Yuan Lane. "Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design." Molecules 25, no. 14 (2020): 3250. http://dx.doi.org/10.3390/molecules25143250.

Full text

Abstract:

A growing body of evidence now suggests that artificial intelligence and machine learning techniques can serve as an indispensable foundation for the process of drug design and discovery. In light of latest advancements in computing technologies, deep learning algorithms are being created during the development of clinically useful drugs for treatment of a number of diseases. In this review, we focus on the latest developments for three particular arenas in drug design and discovery research using deep learning approaches, such as generative adversarial network (GAN) frameworks. Firstly, we re

APA, Harvard, Vancouver, ISO, and other styles

30

Rashid, Masturah Bte Mohd Abdul, and Edward Kai-Hua Chow. "Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine." SLAS TECHNOLOGY: Translating Life Sciences Innovation 24, no. 1 (2018): 124–25. http://dx.doi.org/10.1177/2472630318800774.

Full text

Abstract:

Artificial intelligence holds great promise in transforming how drugs are designed and patients are treated. In a study recently published in Science Translational Medicine, a unique artificial intelligence platform makes efficient use of small experimental datasets to design new drug combinations as well as identify the best drug combinations for specific patient samples. This quadratic phenotypic optimization platform (QPOP) does not rely on previous assumptions of molecular mechanisms of disease, but rather uses system-specific experimental data to determine the best drug combinations for a

APA, Harvard, Vancouver, ISO, and other styles

31

Zhang, Changsheng, and Luhua Lai. "Towards structure-based protein drug design." Biochemical Society Transactions 39, no. 5 (2011): 1382–86. http://dx.doi.org/10.1042/bst0391382.

Full text

Abstract:

Structure-based drug design for chemical molecules has been widely used in drug discovery in the last 30 years. Many successful applications have been reported, especially in the field of virtual screening based on molecular docking. Recently, there has been much progress in fragment-based as well as de novo drug discovery. As many protein–protein interactions can be used as key targets for drug design, one of the solutions is to design protein drugs based directly on the protein complexes or the target structure. Compared with protein–ligand interactions, protein–protein interactions are more

APA, Harvard, Vancouver, ISO, and other styles

32

Bodor, Nicholas, and Peter Buchwald. "Retrometabolic drug design: Principles and recent developments." Pure and Applied Chemistry 80, no. 8 (2008): 1669–82. http://dx.doi.org/10.1351/pac200880081669.

Full text

Abstract:

Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs (SDs) and of chemical delivery systems (CDSs). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and -metabolism relationships; however, they achieve it by different means: whereas SDs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular org

APA, Harvard, Vancouver, ISO, and other styles

33

Ferreira, Elizabeth Igne. "Drug Design and Development for Neglected Diseases." Current Medicinal Chemistry 26, no. 23 (2019): 4298–300. http://dx.doi.org/10.2174/092986732623190927101548.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Ali, Imran. "Homochiral Drug Design and Development by Racemization." Combinatorial Chemistry & High Throughput Screening 10, no. 5 (2007): 326–35. http://dx.doi.org/10.2174/138620707781662835.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

F. Sousa, Sergio, Nuno M.F.S.A. Cerqueira, Pedro A. Fernandes, and Maria Joao Ramos. "Virtual Screening in Drug Design and Development." Combinatorial Chemistry & High Throughput Screening 13, no. 5 (2010): 442–53. http://dx.doi.org/10.2174/138620710791293001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Dranitsaris, G., K. Dorward, E. Hatzimichael, and E. Amir. "Clinical trial design in biosimilar drug development." Investigational New Drugs 31, no. 2 (2012): 479–87. http://dx.doi.org/10.1007/s10637-012-9899-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Eisenberg, Paul R., Rekha Garg, Matthew D. Rotelli, and Kenneth J. Winters. "Cardiovascular Drug Development: Protocol Design and Methodology." Controlled Clinical Trials 21, no. 2 (2000): 140–43. http://dx.doi.org/10.1016/s0197-2456(99)00055-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Preis, Maren, and Jörg Breitkreutz. "Pediatric Drug Development and Dosage Form Design." AAPS PharmSciTech 18, no. 2 (2017): 239–40. http://dx.doi.org/10.1208/s12249-016-0705-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Klein, Donald F., and Ira D. Glick. "Intensive Design to Reinvigorate Psychiatric Drug Development." Journal of Clinical Psychopharmacology 35, no. 6 (2015): 625–27. http://dx.doi.org/10.1097/jcp.0000000000000407.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Goldberg, Robert, Stuart Kauffman, and Eric J. Topol. "Study Design and the Drug Development Process." JAMA 311, no. 19 (2014): 2023. http://dx.doi.org/10.1001/jama.2014.3826.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Johnston, Graham. "A textbook of drug design and development." Trends in Pharmacological Sciences 13 (January 1992): 127–28. http://dx.doi.org/10.1016/0165-6147(92)90044-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Jackson, Robert C. "Predictive Software for Drug Design and Development." Pharmaceutical Development and Regulation 1, no. 3 (2003): 159–68. http://dx.doi.org/10.1007/bf03257375.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Remmel, Rory P. "Drug Metabolism Databases and High-Throughput Testing During Drug Design and Development." Journal of Medicinal Chemistry 45, no. 9 (2002): 1958. http://dx.doi.org/10.1021/jm000383b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Brocks, Dion R., and Neal M. Davies. "Lymphatic Drug Absorption via the Enterocytes: Pharmacokinetic Simulation, Modeling, and Considerations for Optimal Drug Development." Journal of Pharmacy & Pharmaceutical Sciences 21, no. 1s (2018): 254s—270s. http://dx.doi.org/10.18433/jpps30217.

Full text

Abstract:

Most orally administered drugs gain access to the systemic circulation by direct passage from the enterocyte layer of the intestinal tract to the mesenteric blood capillaries. Intestinal lymphatic absorption is another pathway that certain drugs may follow to gain access to the systemic circulation after oral administration. Once absorbed, drug diffuses into the intestinal enterocyte and while in transit may associate with fats as they are processed into chylomicrons within the cells. The chylomicron-associated drug is then secreted from the enterocyte into the lymphatic circulation, thus avoi

APA, Harvard, Vancouver, ISO, and other styles

45

Hameed, Rabia, Afsar Khan, Sehroon Khan, and Shagufta Perveen. "Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development." Anti-Cancer Agents in Medicinal Chemistry 19, no. 5 (2019): 592–98. http://dx.doi.org/10.2174/1871520618666181009163014.

Full text

Abstract:

Background: One of the major goals of computational chemists is to determine and develop the pathways for anticancer drug discovery and development. In recent past, high performance computing systems elicited the desired results with little or no side effects. The aim of the current review is to evaluate the role of computational chemistry in ascertaining kinases as attractive targets for anticancer drug discovery and development. Methods: Research related to computational studies in the field of anticancer drug development is reviewed. Extensive literature on achievements of theorists in this

APA, Harvard, Vancouver, ISO, and other styles

46

Bruch, Eduardo M., Stéphanie Petrella, and Marco Bellinzoni. "Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead." Applied Sciences 10, no. 12 (2020): 4248. http://dx.doi.org/10.3390/app10124248.

Full text

Abstract:

Structure-based and computer-aided drug design approaches are commonly considered to have been successful in the fields of cancer and antiviral drug discovery but not as much for antibacterial drug development. The search for novel anti-tuberculosis agents is indeed an emblematic example of this trend. Although huge efforts, by consortiums and groups worldwide, dramatically increased the structural coverage of the Mycobacterium tuberculosis proteome, the vast majority of candidate drugs included in clinical trials during the last decade were issued from phenotypic screenings on whole mycobacte

APA, Harvard, Vancouver, ISO, and other styles

47

Kearney, Mary-Carmel, Peter E. McKenna, Helen L. Quinn, Aaron J. Courtenay, Eneko Larrañeta, and Ryan F. Donnelly. "Design and Development of Liquid Drug Reservoirs for Microneedle Delivery of Poorly Soluble Drug Molecules." Pharmaceutics 11, no. 11 (2019): 605. http://dx.doi.org/10.3390/pharmaceutics11110605.

Full text

Abstract:

The poor aqueous solubility of existing and emerging drugs is a major issue faced by the pharmaceutical industry. Water-miscible organic solvents, termed co-solvents, can be used to enhance the solubility of poorly soluble substances. Typically, drugs with poor aqueous solubility and Log P > 3 are not amenable to delivery across the skin. This study investigated the use of co-solvents as reservoirs to be used in combination with hydrogel-forming microneedles to enhance the transdermal delivery of hydrophobic compounds, namely Nile red, olanzapine and atorvastatin. A custom-made Franz cell a

APA, Harvard, Vancouver, ISO, and other styles

48

Surabhi, Surabhi, and BK Singh. "COMPUTER AIDED DRUG DESIGN: AN OVERVIEW." Journal of Drug Delivery and Therapeutics 8, no. 5 (2018): 504–9. http://dx.doi.org/10.22270/jddt.v8i5.1894.

Full text

Abstract:

Discovery and development of a new drug is generally known as a very complex process which takes a lot of time and resources. So now a day’s computer aided drug design approaches are used very widely to increase the efficiency of the drug discovery and development course. Various approaches of CADD are evaluated as promising techniques according to their need, in between all these structure-based drug design and ligand-based drug design approaches are known as very efficient and powerful techniques in drug discovery and development. These both methods can be applied with molecular docking to v

APA, Harvard, Vancouver, ISO, and other styles

49

Kelly, D. E., and A. Clark. "Modern approaches to drug discovery and design: setting the scene." Biochemical Society Transactions 31, no. 2 (2003): 428. http://dx.doi.org/10.1042/bst0310428.

Full text

Abstract:

The raison d'ítre for the drug discovery and development process is to provide safe and effective treatments for diseases. Bringing a new drug to market, however, is a time-consuming and expensive process and it remains an imperative for drug companies that they identify ways in which they can accelerate the identification of potential targets and their screening and development in order to maintain a competitive edge. Successful drug discovery efforts include biochemical, biophysical, genetic and immunological approaches, targeting such processes as signal transduction, cell cycle control, ap

APA, Harvard, Vancouver, ISO, and other styles

50

Manal Ali Elhag, Manal Ali Elhag, Nazar Mohammed Gabra Nazar Mohammed Gabra, and M. A. Baseer M. A. Baseer. "Design and Development of Potent Drug Inhibitor to MDM2 Protein in Cancer Through Molecular Docking Studies." Indian Journal of Applied Research 3, no. 3 (2011): 28–30. http://dx.doi.org/10.15373/2249555x/mar2013/10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!